20 articles
NIDCR researchers compared stromal cells from bone marrow, skin, spleen, and fat to identify which best regenerates bone and supports blood formation.
Small trial tests safety of injecting patients' own cardiac stem cells to regrow dead heart tissue and restore function.
Austrian researchers tracked heart attack patients for 5 years after receiving bone marrow cell therapy to assess long-term cardiac outcomes.
Small trial tests autologous bronchial stem cells to repair damaged lung tissue in chronic obstructive pulmonary disease patients.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
65-patient trial tested bone marrow stem cells injected directly into damaged heart muscle to restore function in chronic heart failure.
Researchers tested whether stem cells from healthy hearts could help repair damage in heart attack patients, offering hope for cardiac regeneration.
Researchers compared stem cells from arthritis patients versus healthy donors to assess regenerative therapy potential.
Researchers tested injecting cardiac stem cells directly into heart arteries after heart attacks to promote healing and regeneration.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
New trial explores whether short-term testosterone treatment creates lasting muscle benefits in older men through epigenetic memory.
Researchers tested a novel stem cell therapy using umbilical cord cells on a pericardial matrix to repair heart tissue after heart attacks.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
